[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].

@article{Li2012ASO,
  title={[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].},
  author={Long-Yun Li and Wei Zhong and Meilin Liao and Li Chen and Baohui Han and Zhong-zhen Guan and Shiying Yu and Xuyi Liu and Yi-Long Wu and Guoliang Jiang and Jianming Xu and Jia Jie Chen and Min Tao and Rong-cheng Luo and Weimin Li and Nong Xu and Xiao Zhao and Mengzhao Wang},
  journal={Zhongguo fei ai za zhi = Chinese journal of lung cancer},
  year={2012},
  volume={15 6},
  pages={
          332-9
        }
}
BACKGROUND AND OBJECTIVE The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer (NSCLC) patients who failed to respond to standard treatment or who could not tolerate chemotherapy. The primary objective was to describe the quality of life (QoL), tumor… CONTINUE READING